More about
Tazemetostat
News
June 18, 2020
2 min read
Save
FDA approves Tazverik for follicular lymphoma subset
The FDA granted accelerated approval to tazemetostat for the treatment of adults with relapsed or refractory follicular lymphoma.
News
January 24, 2020
1 min read
Save
FDA approves Tazverik for advanced epithelioid sarcoma
The FDA granted accelerated approval to tazemetostat for patients aged 16 years or older with metastatic or locally advanced epithelioid sarcoma ineligible for complete resection.
News
July 26, 2023
4 min watch
Save
VIDEO: Early relapse after initial chemotherapy major unmet need in follicular lymphoma
In this video, Joshua Brody, MD, director of the lymphoma immunotherapy program at Tisch Cancer Institute at Mount Sinai, discusses major unmet needs in the treatment of follicular lymphoma, including challenges treating early relapsing patients.